Bezlotoxumab Not Yet Recruiting Phase 4 Trials for Clostridium difficile infection recurrence Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT03880539Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection